GlassScriptPhysician profile
Petr Bocek
NPI 1790998458
$7,165.40
in general payments reported to CMS, 2019-2025
19 companies · $735 in 2025
The $735 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $774 · 2021: $1,387 · 2022: $1,504 · 2023: $972 · 2024: $1,200 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,889 · Education: $16.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,889.49 |
| Education | $16.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,544.01 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $2,344.22 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $861.25 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $366.98 | 2020-2023 | Dupixent |
| Amgen INC. | $266.75 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $131.63 | 2022-2025 | |
| Abbvie INC. | $120.76 | 2022 | |
| Kaleo, INC. | $120.67 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $93.73 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $92.13 | 2020-2023 | |
| Alk-Abello, INC | $43.83 | 2019-2024 | Pre-Pen, Standardized Mite D. Farinae, Alternaria Tenuis |
| Organon LLC | $31.56 | 2025 | |
| Optinose US, INC. | $27.69 | 2025 | |
| Boston Scientific Corporation | $24.54 | 2024 | |
| Pfizer INC. | $24.10 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $21.99 | 2022 | |
| Pharming Healthcare, INC. | $19.83 | 2025 | Ruconest |
| Genentech USA, INC. | $16.27 | 2020 | |
| Greer Laboratories, INC. | $13.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Petr Bocek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.